The findings suggest that patients with certain alleles (AR (CAG)M and the heterozygous APEX1 c.444TG genotype) are linked to an increased risk of prostate cancer relapse, even when accounting for conventional clinicopathological variables. The gene discussed is AR; the disease is Familial prostate cancer.